Treatment of AIDS Vacuolar Myelopathy With Methionine
Study Details
Study Description
Brief Summary
The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Detailed Description
Myelopathy is usually a late complication of AIDS, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Between 18 and 80 years of age
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beth Israel Medical Center | New York | New York | United States | 10003 |
Sponsors and Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
- Principal Investigator: Alessandro Di Rocco, MD,
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- R01NS035745